Do not stop donepezil without asking the prescriber to review current benefits, side effects, other medicines, and a taper-and-monitoring plan. Severe Alzheimer's disease alone is not a reason to stop; the decision should turn on whether donepezil still helps this person more than it harms them. Donepezil is a cholinesterase inhibitor, a type of anti-dementia medicine. A supervised deprescribing trial means lowering and possibly stopping it while watching for changes that may show continued benefit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is severe dementia a reason to stop?
- When is a deprescribing trial reasonable?
- What should the medication review cover?
- What should a taper plan include?
- What changes should caregivers track?
Is severe dementia a reason to stop?
No. The NICE dementia guideline NG97 says prescribers should assess continuing need appropriately rather than stop solely because Alzheimer's disease has become severe or cognitive scores are low. The strongest randomized evidence supports caution. In a 2012 New England Journal of Medicine trial, 295 community-dwelling people with moderate-to-severe Alzheimer's disease were followed for 52 weeks.
Those continuing donepezil had a 1.9-point higher cognition score and a 3.0-point lower disability score than those who stopped. That result does not mean everyone benefits indefinitely. Cochrane's 2021 review found that discontinuation may worsen cognition, function, and neuropsychiatric status, but almost all evidence was low or very-low certainty. All participants had Alzheimer's disease, so equal safety cannot be assumed for other dementias.
When is a deprescribing trial reasonable?
According to Deprescribing.com guidance on anti-dementia medicines, a prescriber can consider a trial after more than 12 months without clear benefit, in severe or end-stage dementia, or when side effects materially reduce quality of life. These circumstances prompt an individualized review; they do not automatically settle the decision. The February 2025 U.S.
labeling on DailyMed identifies risks of bradycardia, heart block, and syncope. It also lists these common adverse reactions: Tell the prescriber when each problem began, how often it occurs, and whether it followed a dose change. That detail can help frame the benefit-versus-risk discussion.
- Nausea, diarrhea, or vomiting
- Insomnia
- Muscle cramps or fatigue
- Anorexia, meaning loss of appetite
What should the medication review cover?
ask the prescriber to review every prescription, over-the-counter medicine, and supplement. Anticholinergic drugs deserve particular attention because they can oppose cholinesterase-inhibitor effects and impair cognition.
Deprescribing.com suggests considering withdrawal of the anticholinergic first when both types are being used. Bring a complete medication list and ask:.
- Is any medicine anticholinergic?
- If so, should that medicine be addressed before donepezil?
- What observable benefit is donepezil providing now?
- Could current symptoms be adverse reactions?
- What findings would favor continuation or a supervised stopping trial?
What should a taper plan include?
Deprescribing.com suggests an individualized taper, generally halving the daily dose every four weeks. The plan should pause if cognition, daily function, overall clinical condition, or behavior and mood worsen. Before the first reduction, get clear instructions covering: An unmonitored abrupt stop does not provide the same structured opportunity to detect decline and reconsider the decision.
- The starting dose and reduction dates
- Which abilities and behaviors provide the baseline
- Who will observe and record changes
- Which changes require a pause
- Whom to contact before another dose reduction
What changes should caregivers track?
Deprescribing guidance recommends monitoring every one to two weeks during dose reductions and for at least four weeks after cessation. Watch for: Use specific observations rather than broad labels. For example, record what changed, when it began, how often it happens, and how it affects daily care.
A decline after dose reduction does not prove by itself that stopping caused it. The prescriber should consider its timing and other possible explanations. If meaningful worsening appears, pause the plan and contact the prescriber before the next reduction.
- Agitation or other behavioral changes
- Apathy
- Worsening cognition
- Reduced ability to manage usual daily activities
